Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Epigenetics

• Publication date

  2013-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.4161/epi.24916PMID 23771052PMCID PMC3857345
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA Methylation of GSTP1 in Human Prostate Tissues: Pyrosequencing Analysis

  2012cited by this paper
• The emerging role of histone lysine demethylases in prostate cancer

  2012cited by this paper
• Global Methylation Profiling for Risk Prediction of Prostate Cancer

  2012cited by this paper
• Cyclopentenone prostaglandins with dienone structure promote cross-linking of the chemoresistance-inducing enzyme Glutathione S-Transferase P1-1

  2010cited by this paper
• Mechanistic Insights on the Inhibition of C5 DNA Methyltransferases by Zebularine

  2010cited by this paper
• Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells

  2010cited by this paper
• DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine.

  2010cited by this paper
• Role of glutathione transferases in the mechanism of brostallicin activation.

  2010cited by this paper
• An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer

  2010cited by this paper
• Cyclopentenone Prostaglandins with Dienone Structure Promote Cross-Linking of the Chemoresistance-Inducing Enzyme Glutathione Transferase P1-1

  2010cited by this paper
• Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity

  2009cited by this paper
• A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer.

  2007cited by this paper
• Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.

  2007cited by this paper
• Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.

  2007cited by this paper
• Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia

  2005cited by this paper
• Enhancement of In vitro and In vivo Tumor Cell Radiosensitivity by the DNA Methylation Inhibitor Zebularine

  2005cited by this paper
• Zebularine: a new drug for epigenetic therapy.

  2004cited by this paper
• Cytotoxic α-Halogenoacrylic Derivatives of Distamycin A and Congeners

  2004cited by this paper
• Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells

  2004cited by this paper
• Preferential response of cancer cells to zebularine.

  2004cited by this paper
• Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.

  2004cited by this paper
• Zebularine: a candidate for epigenetic cancer therapy.

  2004cited by this paper
• Brostallicin: a new concept in minor groove DNA binder development

  2004cited by this paper
• The discovery of a new potential anticancer drug: a case history.

  2003cited by this paper
• Inhibition of DNA methylation and reactivation of silenced genes by zebularine.

  2003cited by this paper
• Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.

  2003cited by this paper
• Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases.

  2002cited by this paper
• Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.

  2002cited by this paper
• Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.

  2000cited by this paper
• Cytotoxic alpha-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety.

  2000cited by this paper
• Cytotoxic α-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety

  2000cited by this paper
• A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

  1999cited by this paper
• High frequency of alterations in DNA methylation in adenocarcinoma of the prostate

  1999cited by this paper
• Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia.

  1998cited by this paper
• Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide.

  1996cited by this paper
• Purification of an alpha class glutathione S-transferase from melphalan-resistant Chinese hamster ovary cells and demonstration of its ability to catalyze melphalan-glutathione adduct formation.

  1994cited by this paper
• Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes.

  1994cited by this paper

• PM2.5-induced DNA oxidative stress in A549 cells and regulating mechanisms by GST DNA methylation and Keap1/Nrf2 pathway

  2024cites this paper
• Impact of DNA methylation on ADME gene expression, drug disposition, and efficacy

  2022influential citation
• Epigenetics and precision medicine in prostate cancer

  2022cites this paper
• The paradigm of drug resistance in cancer: an epigenetic perspective

  2022cites this paper
• DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1

  2022cites this paper
• Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer

  2020cites this paper
• Targeting DNA Methyltranferases in Urological Tumors

  2018cites this paper
• Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic.

  2018cites this paper
• Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review

  2018cites this paper
• Pan-Cancer Analysis Reveals the Functional Importance of Protein Lysine Modification in Cancer Development

  2018cites this paper
• Epigenetic modulators as therapeutic targets in prostate cancer

  2016cites this paper
• Mutagen Synergy: Hypermutability Generated by Specific Pairs of Base Analogs

  2016cites this paper
• Decreased expression of glutathione S-transferase pi correlates with poorly differentiated grade in patients with oral squamous cell carcinoma.

  2015cites this paper
• Brain feminization requires active repression of masculinization via DNA methylation

  2015cites this paper
• DNA Methylation in Acquired Drug Resistance

  2015cites this paper
• Brain feminization requires active repression of masculinization via DNA methylation

  2015cites this paper
• Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells.

  2015cites this paper
• Novel Epigenetic Target Therapy for Prostate Cancer: A Preclinical Study

  2014cites this paper
• Human endometrial DNA methylome is cycle-dependent and is associated with gene expression regulation.

  2014cites this paper
• Glutathione S-conjugates as prodrugs to target drug-resistant tumors

  2014cites this paper